Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 May 2010

Lam Elaine T, Ringel Matthew D, Kloos Richard T, Prior Thomas W, Knopp Michael V, Liang Jiachao, Sammet Steffen, Hall Nathan C, Wakely Paul E, Vasko Vasyl V, Saji Motoyasu, Snyder Pamela J, Wei Lai, Arbogast Daria, Collamore Minden, Wright John J, Moley Jeffrey F, Villalona-Calero Miguel A, Shah Manisha H

Abstract excerpt

PURPOSE: Mutations in the RET proto-oncogene and vascular endothelial growth factor receptor (VEGFR) activity are critical in the pathogenesis of medullary thyroid cancer (MTC). Sorafenib, a multikinase inhibitor targeting Ret and VEGFR, showed antitumor activity in preclinical studies of MTC. PATIENTS AND METHODS: In this phase II trial of sorafenib in patients with advanced MTC, the primary end point was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzenesulfonates
Share to Carcinoma, Medullary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Niacinamide

Share to Phenylurea Compounds

Share to Positron-Emission Tomography

Share to Proto-Oncogene Proteins c-ret

Share to Receptors, Vascular Endothelial Growth Factor

Share to Sorafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 20368568
DOI: 10.1200/JCO.2009.25.0068
PMCID: PMC2881718

Genes

RET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.PMID 20368568Read ↗

Targeting RET Receptor Tyrosine Kinase Activation in CancerSemantic proximity Read ↗

Medullary Thyroid Cancer: Molecular Biology and Novel Molecular TherapiesSemantic proximity Read ↗

BRAF inhibitors: experience in thyroid cancer and general review of toxicity.Semantic proximity Read ↗

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.Semantic proximity Read ↗

Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid CancerSemantic proximity Read ↗

Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.Semantic proximity Read ↗

Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.Semantic proximity Read ↗

Sorafenib in Metastatic Papillary Thyroid Carcinoma with BRAF K601E Mutation on Liquid Biopsy: A Case Report and Literature Review.Semantic proximity Read ↗

Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.Semantic proximity Read ↗

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.Semantic proximity Read ↗

Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.Semantic proximity Read ↗

(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.